Bristol Myers Squibb (CELG-RI) Selling, General & Administrative (2009 - 2026)
Bristol Myers Squibb (CELG-RI) Selling, General & Administrative (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
SG&A (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-2.86 Bn |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
2.93 Bn |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
6.03 Bn |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
3.58 Bn |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
2.70 Bn |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
1.60 Bn |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
1.45 Bn |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
2.96 Bn |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
1.62 Bn |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
1.62 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
1.62 Bn |
| Dec 31, 2025 |
2.18 Bn |
| Sep 30, 2025 |
1.79 Bn |
| Jun 30, 2025 |
1.71 Bn |
| Mar 31, 2025 |
1.58 Bn |
| Dec 31, 2024 |
2.14 Bn |
| Sep 30, 2024 |
1.98 Bn |
| Jun 30, 2024 |
1.93 Bn |
| Mar 31, 2024 |
2.37 Bn |
| Dec 31, 2023 |
2.07 Bn |
| Sep 30, 2023 |
2.00 Bn |
| Jun 30, 2023 |
1.93 Bn |
| Mar 31, 2023 |
1.76 Bn |
| Dec 31, 2022 |
2.27 Bn |
| Sep 30, 2022 |
1.93 Bn |
| Jun 30, 2022 |
1.79 Bn |
| Mar 31, 2022 |
1.83 Bn |
| Dec 31, 2021 |
2.35 Bn |
| Sep 30, 2021 |
1.79 Bn |
| Jun 30, 2021 |
1.88 Bn |
